Reuters, others, quote APC on semaglutide coming out of shortage

The Reuters story, “Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice” was picked up by a lot of news outlets including PharmaPhorum (“Compounders cast adrift”), and Axios (“Copycat Ozempic makers brace for crackdown”).

The story quotes us on one of our most important points: Did the FDA consider the huge demand for FDA-approved semaglutide injections about to be unleashed? There might be enough now, but what happens when 200,000 more prescriptions for Ozempic and Wegovy hit pharmacies?

Other outlets had similar stories to tell — and, of course, included APC’s perspective. Those included the Washington Post (“FDA says Ozempic shortage is over, chilling boom in off-brand versions”) and The Hill (“Ozempic and Wegovy officially moved off FDA’s drug shortage list”). Meanwhile, FiercePharma had two stories, one focused on Hims & Hers’ stock price, the other on the effect on the overall compounding marketplace.